Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis

Detalles Bibliográficos
Autores principales: Hottinger, Andreas F., de Micheli, Rita, Guido, Vanessa, Karampera, Alexandra, Hagmann, Patric, Du Pasquier, Renaud
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Clinical/Scientific Notes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225924/
https://www.ncbi.nlm.nih.gov/pubmed/30465016
http://dx.doi.org/10.1212/NXI.0000000000000439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225924/
https://www.ncbi.nlm.nih.gov/pubmed/30465016
http://dx.doi.org/10.1212/NXI.0000000000000439

Ejemplares similares